Lack of effectiveness of Bebtelovimab monoclonal antibody among high-risk patients with SARS-Cov-2 Omicron during BA.2, BA.2.12.1 and BA.5 subvariants dominated era
Sridhara et al., PLOS ONE, doi:10.1371/journal.pone.0279326
https://c19early.org/sridhara.html